Search

Multivariate pattern analysis (MVPA) has played an extensive role in interpreting brain activity, which has been applied in studies with modalities such as functional Magnetic Resonance Imaging (fMRI), Magnetoencephalography (MEG) and Electroencephalography (EEG). The advent of wearable MEG systems based on optically pumped magnetometers (OPMs), i.e., OP-MEG, has broadened the application of bio-magnetism in the realm of neuroscience. Nonetheless, it also raises challenges in temporal decoding analysis due to the unique attributes of OP-MEG itself. The efficacy of decoding performance utilizing multimodal fusion, such as MEG-EEG, also remains to be elucidated. In this regard, we investigated the impact of several factors, such as processing methods, models and modalities, on the decoding outcomes of OP-MEG. Our findings indicate that the number of averaged trials, dimensionality reduction (DR) methods, and the number of cross-validation folds significantly affect the decoding performance of OP-MEG data. Additionally, decoding results vary across modalities and fusion strategy. In contrast, decoder type, resampling frequency, and sliding window length exert marginal effects. Furthermore, we introduced mutual information (MI) to investigate how information loss due to OP-MEG data processing affect decoding accuracy. Our study offers insights for linear decoding research using OP-MEG and expand its application in the fields of cognitive neuroscience. [ABSTRACT FROM AUTHOR]

In the face of the increasing scale of port video surveillance systems, edge computing is gradually used to improve the real-time processing efficiency of surveillance systems and reduce the load on the cloud with the advantages of distributed computing. In order to improve the security factor of terminal access in the edge computing environment, this paper proposes a decentralized terminal security access authentication system based on blockchain, which realizes the identity registration, revocation and mutual authentication of two interfaces between terminal devices and edge computing through the smart contract technology of blockchain, and establishes a trusted channel for data transmission between terminals and edge nodes. Through the functional test of the system and the security analysis of the system on the Hyperledger Fabric platform, it shows that the system has more security attributes and higher security.

Introduction: Costimulatory molecules are putative novel targets or potential additions to current available immunotherapy, but their expression patterns and clinical value in triple-negative breast cancer (TNBC) are to be clarified., Methods: The gene expression profiles datasets of TNBC patients were obtained from The Cancer Genome Atlas and the Gene Expression Omnibus databases. Diagnostic biomarkers for stratifying individualized tumor immune microenvironment (TIME) were identified using the Least Absolute Shrinkage and Selection Operator (LASSO) and Support Vector Machine-Recursive Feature Elimination (SVM-RFE) algorithms. Additionally, we explored their associations with response to immunotherapy via the multiplex immunohistochemistry (mIHC)., Results: A total of 60 costimulatory molecule genes (CMGs) were obtained, and we determined two different TIME subclasses ("hot" and "cold") through the K-means clustering method. The "hot" tumors presented a higher infiltration of activated immune cells, i.e., CD4 memory-activated T cells, resting NK cells, M1 macrophages, and CD8 T cells, thereby enriched in the B cell and T cell receptor signaling pathways. LASSO and SVM-RFE algorithms identified three CMGs (CD86, TNFRSF17 and TNFRSF1B) as diagnostic biomarkers. Following, a novel diagnostic nomogram was constructed for predicting individualized TIME status and was validated with good predictive accuracy in TCGA, GSE76250 and GSE58812 databases. Further mIHC conformed that TNBC patients with high CD86, TNFRSF17 and TNFRSF1B levels tended to respond to immunotherapy., Conclusion: This study supplemented evidence about the value of CMGs in TNBC. In addition, CD86, TNFRSF17 and TNFRSF1B were found as potential biomarkers, significantly promoting TNBC patient selection for immunotherapeutic guidance., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Zhang, Zhai, Ma, Wu, Cai, Huang, Zhou and Duan.)